...
AMRNMID

Amarin Corporation plc

HealthcareBiotechnology
$13.80
$0.00(-2.27%)
52W$7.08
$20.90
FinancialsValuationvs UTHR
Updated Mar 1, 12:00 AM
RSI40
RS Rating36/99
Beta0.84
Volatility60%
F-Score2/9
Mkt Cap$5.7B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Amarin Corporation plc is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 36), showing significant lag compared to the market leaders. Earnings growth of 70% provides fundamental context to the price action. Investors should exercise caution due to high volatility (60% annualized), which requires wider risk management.

Relative Strength
36
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
0.84
vs S&P 500
DEFENSIVE
52W Position
49%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$14.80
50 SMA > 100 SMA$15.86
100 SMA > 150 SMA$15.73
150 SMA > 200 SMA$15.28

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$14.89-7.32%BELOW
50 SMA$14.80-6.74%BELOW
100 SMA$15.86-12.99%BELOW
150 SMA$15.73-12.29%BELOW
200 SMA$15.28-9.66%BELOW

Price Performance

1D-2.3%
1W-11.7%
1M-8.4%
3M-13.6%
6M-10.4%
YTD+0.6%
1Y+27.3%
3Y-30.2%
52-Week Trading Range49% from low
$13.80
52W Low$7.08
52W High$20.90

Technical Indicators

RSI (14)BEARISH
40.0
305070
VCP ScoreCOOL
6/10
Base depth: 30.4%

Risk Profile

Beta
0.84
52W Vol
60%
ATR
$0.70
Max DD (1Y)
-33%

Volume Analysis

Today
13
50D Avg
76.0K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24-717%
$-2.37
Q1'25-55%
$-0.76
Q2'25-1019%
$-0.68
Q3'25+70%
$-0.37
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+15.48%
5 Years:-11.86%
3 Years:-26.81%
TTM:-6.21%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-117.03%

Stock Price CAGR

10 Years:-7.22%
5 Years:-35.52%
3 Years:-30.21%
1 Year:+27.31%

Return on Equity

10Y Avg:-45.4%
5Y Avg:-8.9%
3Y Avg:-14.3%
Last Year:-18.8%

Key Metrics

Market Cap$5.7B
Gross Margin35.6%
Net Margin-35.9%
Piotroski F-Score2/9

More AMRN Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

AMRN vs UTHRUTHRZLABALKSADMA

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 36 meansAMRN outperformed 36% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.84 means 16% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 2/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 6/10 with COOL status.

Frequently Asked Questions

Is AMRN in an uptrend right now?

AMRN has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is AMRN overbought or oversold?

AMRN's RSI (14) is 40. The stock is in neutral territory, neither overbought nor oversold.

Is AMRN outperforming the market?

AMRN has a Relative Strength (RS) Rating of 36 out of 99. AMRN is currently lagging the broader market.

Where is AMRN in its 52-week range?

AMRN is trading at $13.80, which is 66% of its 52-week high ($20.90) and 49% above its 52-week low ($7.08).

How volatile is AMRN?

AMRN has a Beta of 0.84 and 52-week volatility of 60%. It's less volatile than the S&P 500 - generally more stable.